Intelligence · Patents
Patents expiring in 2029
Annual patent cliff calendar for 2029 — US pharmaceutical patents by expiration date.
- Patents
- 713
Quick answer
713 indexed pharmaceutical patents have expiration dates in 2029. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 7576175
Alpha-4 beta-1 integrin ligands for imaging and therapy
granted -
US 7576100
Muscarinic agonists
granted -
US 7575742
Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
granted -
US 7576076
Modified pyrimidine glucocorticoid receptor modulators
granted -
US 7576130
Dihydroxyl compounds and compositions for cholesterol management and related uses
granted -
US 7576078
Tetrahydroquinoline analogues as muscarinic agonists
granted -
US 7576065
Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
granted -
US 7576053
Methods and compositions for treating degenerative bone disorders
granted -
US 7575904
Polymer grafting by polysaccharide synthases
granted -
US 7576050
GLP-1 exendin-4 peptide analogs and uses thereof
granted -
US 7576194
UspA2 nucleic acid of moraxella catarrhalis
granted -
US 7575873
Reagents for diagnosing, imaging and treating atherosclerotic disease
granted -
US 7579014
Mesoporous compositions for use in drug delivery
granted -
US 7578998
Chimeric cytokine of IL-7 and beta-chain of HGF and methods of use
granted -
US 7579319
Methods for improving the structure and function of arterioles
granted -
US 7579333
Therapy using a combination of raloxifene and alendronate
granted -
US 7579444
Polymer-factor IX moiety conjugates
granted -
US 7579453
Variants of human taste receptor genes
granted -
US 7579451
Oligonucleotides comprising a modified or non-natural nucleobase
granted -
US 7579357
Dipeptidyl peptidase inhibitors
granted -
US 7579188
Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
granted -
US 7579006
Method of treating immune pathologies with low dose estrogen
granted -
US 7579173
Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using the same
granted -
US 7582289
Viruses for the treatment of cellular proliferative disorders
granted -
US 7582605
Phosphorus-containing hepatitis C serine protease inhibitors
granted -
US 7582651
Pyrrolopyridine derivative and use thereof
granted -
US 7582662
Body weight gain inhibitor
granted -
US 7582425
Atlastin
granted -
US 7582676
2-phenylpyran-4-one derivatives as selective COX-2 inhibitors
granted -
US 7582736
Prostate cancer specific internalizing human antibodies
granted -
US 7582744
Chemically modified oligonucleotides
granted -
US 7582765
Aryl aniline β2 adrenergic receptor agonists
granted -
US 7582759
Diastereomeric purification of rosuvastatin
granted -
US 7582745
Compositions and methods for inhibiting expression of Nav1.8 gene
granted -
US 7582680
Methods and compositions for treating mammalian spinal cord injuries
granted -
US 7582641
Gyrase inhibitors and uses thereof
granted -
US 7582623
Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
granted -
US 7582648
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
granted -
US 7582442
Methods and compositions for using aleveolar macrophage phospholipase A2
granted -
US 7582307
Dermatological composition
granted -
US 7582312
Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
granted -
US 7582298
High affinity antibodies to human IL-6 receptor
granted -
US 7582284
Particulate materials
granted -
US 7582281
Ethylenedicysteine (EC)-drug conjugates compositions and methods for tissue specific disease imaging
granted -
US 7582279
Blood-pool carrier for lipophilic imaging agents
granted -
US 7581864
Tooth bleaching process
granted -
US 7581846
Dental light devices having an improved heat sink
granted -
US 7582430
Immunoliposome-nucleic acid amplification (ILNAA) assay
granted
Frequently asked questions
How many pharma patents expire in 2029?
713 published patents in our USPTO index have expiration dates falling in calendar year 2029.